11β-Prostaglandin F2α-d4
(Synonyms: 9α,11βPGF2αd4, 11βPGF2αd4, 11epi PGF2αd4) 目录号 : GC46412
An internal standard for the quantification of 11β-PGF F2α
Cas No.:1240398-18-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
11β-Prostaglandin F2α-d4 (11β-PGF2α-d4) is intended for use as an internal standard for the quantification of 11β-PGF2α by GC- or LC-MS. 11β-PGF2α is the primary metabolite of PGD2 .1 It is formed from PGD2 via the NADPH-dependent aldo-keto reductase PGF synthase in the liver or lung.2 11β-PGF2α induces contraction of isolated cat iris sphincter, which endogenously expresses high levels of PGF2α (FP) receptors, with an EC50 value of 0.045 µM.1 It also induces contraction of isolated human bronchial smooth muscle when used at concentrations ranging from 0.1 to 30 µM.3 11β-PGF2α (0.1 and 1 µM) induces phosphorylation of ERK and CREB, as well as increases the viability of MCF-7 breast cancer cells stably expressing the FP receptor when used at concentrations of 0.1 and 1 µM.4
1.Giles, H., Bolofo, M.L., Lydford, S.J., et al.A comparative study of the prostanoid receptor profile of 9α 11 β-prostaglandin F2 and prostaglandin D2Br. J. Pharmacol.104(2)541-549(1991) 2.Watanabe, K.Prostaglandin F synthaseProstaglandins Other Lipid Mediat.68-69401-407(2002) 3.Coleman, R.A., and Sheldrick, R.L.G.Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptorsBr. J. Pharmacol.96(3)688-692(1989) 4.Yoda, T., Kikuchi, K., Miki, Y., et al.11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancerMol. Cell. Endocrinol.413236-247(2015)
| Cas No. | 1240398-18-8 | SDF | |
| 别名 | 9α,11βPGF2αd4, 11βPGF2αd4, 11epi PGF2αd4 | ||
| Canonical SMILES | O[C@@H]1[C@H](/C=C/[C@H](O)CCCCC)[C@@H](C/C=C\C([2H])([2H])C([2H])([2H])CC(O)=O)[C@@H](O)C1 | ||
| 分子式 | C20H30D4O5 | 分子量 | 358.5 |
| 溶解度 | Ethanol: 100 mg/ml,DMF: 100 mg/ml,DMSO: 100 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7894 mL | 13.947 mL | 27.894 mL |
| 5 mM | 0.5579 mL | 2.7894 mL | 5.5788 mL |
| 10 mM | 0.2789 mL | 1.3947 mL | 2.7894 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。